ASBP
Aspire Biopharma Holdings, Inc.
Biotechnology
Market Cap$7M
5Y Perf.-98.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ASBP vs CMPS
Revenue, margins, valuation, and 5-year total return — side by side.
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.+117.9%
ASBP vs CMPS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ASBP | CMPS |
|---|---|---|
| Industry | Biotechnology | Medical - Care Facilities |
| Market Cap | $7M | $902M |
| Revenue (TTM) | $2K | $0.00 |
| Net Income (TTM) | $-32M | $-288M |
| Gross Margin | 45.5% | — |
| Operating Margin | -10314.4% | — |
| Total Debt | $1M | $21M |
| Cash & Equiv. | $4K | $150M |
ASBP vs CMPS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ASBP
CMPS
| Stock | Jan 25 | May 26 | Return |
|---|---|---|---|
| Aspire Biopharma Ho… (ASBP) | 100 | 1.2 | -98.8% |
| COMPASS Pathways plc (CMPS) | 100 | 217.9 | +117.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASBP vs CMPS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CMPS leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
ASBP
Aspire Biopharma Holdings, Inc.
The Specific-Use Pick
In this particular matchup, ASBP is outpaced on most metrics by others in the set.
Best for: healthcare exposure
CMPS
COMPASS Pathways plc
The Income Pick
CMPS carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.33
- EPS growth -33.9%
- -67.6% 10Y total return vs ASBP's -98.7%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CMPS | -85.7% revenue growth vs ASBP's -13.7% |
| Quality / Margins | CMPS | 1.3% margin vs ASBP's -16K% |
| Stability / Safety | CMPS | Beta 1.33 vs ASBP's 1.74 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CMPS | +151.1% vs ASBP's -52.6% |
| Efficiency (ROA) | CMPS | -106.8% ROA vs ASBP's -13.2% |
ASBP vs CMPS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCMPSLAGGINGASBP
ASBPAspire Biopharma Hold…
0leads
CMPSCOMPASS Pathways plc
3leads
6 Total Categories
CATEGORYLEADERvs ASBPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
CMPS1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
CMPS6/6
Risk & VolatilityBeta, volatility, and downside exposure
CMPS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
ASBP and CMPS operate at a comparable scale, with $1,941 and $0 in trailing revenue.
| Metric | ASBPAspire Biopharma … | CMPSCOMPASS Pathways … |
|---|---|---|
| RevenueTrailing 12 months | $1,941 | $0 |
| EBITDAEarnings before interest/tax | -$28M | -$179M |
| Net IncomeAfter-tax profit | -$32M | -$288M |
| Free Cash FlowCash after capex | -$4M | -$157M |
| Gross MarginGross profit ÷ Revenue | +45.5% | — |
| Operating MarginEBIT ÷ Revenue | -10314.4% | — |
| Net MarginNet income ÷ Revenue | -16352.0% | — |
| FCF MarginFCF ÷ Revenue | -1811.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | -58.7% |
Insufficient data to determine a leader in this category.
Valuation Metrics
CMPS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ASBPAspire Biopharma … | CMPSCOMPASS Pathways … |
|---|---|---|
| Market CapShares × price | $7M | $902M |
| Enterprise ValueMkt cap + debt − cash | $9M | $774M |
| Trailing P/EPrice ÷ TTM EPS | -0.60x | -3.05x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | — | — |
| Price / FCFMarket cap ÷ FCF | — | — |
CMPS leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — ASBP and CMPS each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
| Metric | ASBPAspire Biopharma … | CMPSCOMPASS Pathways … |
|---|---|---|
| ROE (TTM)Return on equity | — | -3.4% |
| ROA (TTM)Return on assets | -13.2% | -106.8% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | — | -2.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $1M | -$129M |
| Cash & Equiv.Liquid assets | $3,633 | $150M |
| Total DebtShort + long-term debt | $1M | $21M |
| Interest CoverageEBIT ÷ Interest expense | -9.19x | -52.40x |
Evenly matched — ASBP and CMPS each lead in 2 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
CMPS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CMPS five years ago would be worth $2,756 today (with dividends reinvested), compared to $135 for ASBP. Over the past 12 months, CMPS leads with a +151.1% total return vs ASBP's -52.6%. The 3-year compound annual growth rate (CAGR) favors CMPS at 3.5% vs ASBP's -76.2% — a key indicator of consistent wealth creation.
| Metric | ASBPAspire Biopharma … | CMPSCOMPASS Pathways … |
|---|---|---|
| YTD ReturnYear-to-date | +13.1% | +43.4% |
| 1-Year ReturnPast 12 months | -52.6% | +151.1% |
| 3-Year ReturnCumulative with dividends | -98.7% | +11.0% |
| 5-Year ReturnCumulative with dividends | -98.7% | -72.4% |
| 10-Year ReturnCumulative with dividends | -98.7% | -67.6% |
| CAGR (3Y)Annualised 3-year return | -76.2% | +3.5% |
CMPS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
CMPS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CMPS is the less volatile stock with a 1.33 beta — it tends to amplify market swings less than ASBP's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CMPS currently trades 92.0% from its 52-week high vs ASBP's 6.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ASBPAspire Biopharma … | CMPSCOMPASS Pathways … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 1.33x |
| 52-Week HighHighest price in past year | $2.45 | $10.21 |
| 52-Week LowLowest price in past year | $0.05 | $2.25 |
| % of 52W HighCurrent price vs 52-week peak | +6.3% | +92.0% |
| RSI (14)Momentum oscillator 0–100 | 29.8 | 68.1 |
| Avg Volume (50D)Average daily shares traded | 15.0M | 3.7M |
CMPS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ASBPAspire Biopharma … | CMPSCOMPASS Pathways … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $17.83 |
| # AnalystsCovering analysts | — | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CMPS leads in 3 of 6 categories — strongest in Valuation Metrics and Total Returns. 1 category is tied.
Best OverallCOMPASS Pathways plc (CMPS)Leads 3 of 6 categories
Loading custom metrics...
ASBP vs CMPS: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ASBP or CMPS a better buy right now?
Analysts rate COMPASS Pathways plc (CMPS) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ASBP or CMPS?
Over the past 5 years, COMPASS Pathways plc (CMPS) delivered a total return of -72.
4%, compared to -98. 7% for Aspire Biopharma Holdings, Inc. (ASBP). Over 10 years, the gap is even starker: CMPS returned -67. 6% versus ASBP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ASBP or CMPS?
By beta (market sensitivity over 5 years), COMPASS Pathways plc (CMPS) is the lower-risk stock at 1.
33β versus Aspire Biopharma Holdings, Inc. 's 1. 74β — meaning ASBP is approximately 31% more volatile than CMPS relative to the S&P 500.
04Which has better profit margins — ASBP or CMPS?
COMPASS Pathways plc (CMPS) is the more profitable company, earning 0.
0% net margin versus -16352. 0% for Aspire Biopharma Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CMPS leads at 0. 0% versus -10314. 4% for ASBP. At the gross margin level — before operating expenses — ASBP leads at 45. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ASBP or CMPS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ASBP or CMPS better for a retirement portfolio?
For long-horizon retirement investors, COMPASS Pathways plc (CMPS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Aspire Biopharma Holdings, Inc. (ASBP) carries a higher beta of 1. 74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CMPS: -67. 6%, ASBP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ASBP and CMPS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.